Chiesi Farmaceutici has been awarded with the "Special Mention fro innovation" for Holoclar, during the ceremony of the Galeno Award, a prize promoting the most important progresses in the pharmaceutical research. The Galeno Award is considered today the Nobel prize in the Pharmaceutical area and…
Chiesi Farmaceutici SpA, a leading international pharmaceutical company focused in the respiratory, neonatology and special care therapeutic areas, closed 2013 with a turnover of more than 1,236 million euro, an increase of 11,8% compared to 2012 (+14% at constant exchange rates). "All our global…
Foster is a fixed combination of beclomethasone dipropionate (corticosteroid) and formoterol fumarate (a long-acting β2-agonist with rapid onset of effect) to be taken by inhalation. In 2006 the drug was approved for the maintenance therapy of asthma; after its first launch in Germany on October…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
